• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease.

作者信息

Stoker Thomas B, Andresen Katie E R, Barker Roger A

机构信息

John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.

Wellcome Trust-Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.

出版信息

Mov Disord. 2021 Jan;36(1):263-264. doi: 10.1002/mds.28359. Epub 2020 Oct 30.

DOI:10.1002/mds.28359
PMID:33125799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7894279/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49f4/7894279/af4f3f6e1666/MDS-36-263-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49f4/7894279/af4f3f6e1666/MDS-36-263-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/49f4/7894279/af4f3f6e1666/MDS-36-263-g001.jpg

相似文献

1
Hydrocephalus Complicating Intrathecal Antisense Oligonucleotide Therapy for Huntington's Disease.脑积水并发鞘内注射反义寡核苷酸治疗亨廷顿舞蹈病
Mov Disord. 2021 Jan;36(1):263-264. doi: 10.1002/mds.28359. Epub 2020 Oct 30.
2
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.亨廷顿病的潜在疾病修饰治疗方法：经验教训和未来机遇。
Lancet Neurol. 2022 Jul;21(7):645-658. doi: 10.1016/S1474-4422(22)00121-1.
3
Is Huntington's disease on the threshold of a new era in treatment?亨廷顿舞蹈症的治疗是否即将开启新纪元？
Neurodegener Dis Manag. 2019 Oct;9(5):255-258. doi: 10.2217/nmt-2019-0015.
4
[Gene Therapy for Huntington Disease].[亨廷顿病的基因治疗]
Fortschr Neurol Psychiatr. 2023 Apr;91(4):141-146. doi: 10.1055/a-2042-2338. Epub 2023 Apr 11.
5
Huntingtin-lowering strategies for Huntington's disease.降低亨廷顿病亨廷顿蛋白的策略。
Expert Opin Investig Drugs. 2020 Oct;29(10):1125-1132. doi: 10.1080/13543784.2020.1804552. Epub 2020 Aug 14.
6
Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.在亨廷顿舞蹈症的YAC128小鼠模型中，反义寡核苷酸介导的转录失调校正与行为改善相关。
J Huntingtons Dis. 2013;2(2):217-28. doi: 10.3233/JHD-130057.
7
Failure of genetic therapies for Huntington's devastates community.亨廷顿舞蹈症基因疗法的失败令学界倍感挫败。
Nature. 2021 May;593(7858):180. doi: 10.1038/d41586-021-01177-7.
8
Translating Antisense Technology into a Treatment for Huntington's Disease.将反义技术转化为亨廷顿舞蹈症的一种治疗方法。
Methods Mol Biol. 2018;1780:497-523. doi: 10.1007/978-1-4939-7825-0_23.
9
Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.使用三环 DNA 反义寡核苷酸降低突变型亨廷顿蛋白作为亨廷顿病的治疗方法。
Nucleic Acid Ther. 2019 Oct;29(5):256-265. doi: 10.1089/nat.2018.0775. Epub 2019 Jun 11.
10
Antisense oligonucleotides might change the therapeutic landscape for Huntington's disease.反义寡核苷酸可能会改变亨廷顿病的治疗前景。
Lancet Neurol. 2019 Oct;18(10):911-912. doi: 10.1016/S1474-4422(19)30329-1.

引用本文的文献

1
Intra-Arterial Administration of Stem Cells and Exosomes for Central Nervous System Disease.干细胞和外泌体动脉内给药治疗中枢神经系统疾病
Int J Mol Sci. 2025 Jul 31;26(15):7405. doi: 10.3390/ijms26157405.
2
An Imperative for Public Sharing of Adverse Events of Gene Therapy Trials.基因治疗试验不良事件公开分享的必要性。
JAMA Neurol. 2025 May 1;82(5):429-430. doi: 10.1001/jamaneurol.2024.4671.
3
Overview of ADNI MRI.ADNI MRI 概述。

本文引用的文献

1
Huntingtin-lowering strategies for Huntington's disease.降低亨廷顿病亨廷顿蛋白的策略。
Expert Opin Investig Drugs. 2020 Oct;29(10):1125-1132. doi: 10.1080/13543784.2020.1804552. Epub 2020 Aug 14.
2
Targeting Huntingtin Expression in Patients with Huntington's Disease.靶向亨廷顿病患者的亨廷顿蛋白表达。
N Engl J Med. 2019 Jun 13;380(24):2307-2316. doi: 10.1056/NEJMoa1900907. Epub 2019 May 6.
3
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.依库珠单抗治疗晚发性脊髓性肌萎缩症的疗效观察：一项随机、双盲、安慰剂对照 3 期试验
Alzheimers Dement. 2024 Oct;20(10):7350-7360. doi: 10.1002/alz.14166. Epub 2024 Sep 11.
4
Neuronal UBE3A substrates hold therapeutic potential for Angelman syndrome.神经UBE3A 底物为 Angelman 综合征提供了治疗潜力。
Curr Opin Neurobiol. 2024 Oct;88:102899. doi: 10.1016/j.conb.2024.102899. Epub 2024 Aug 9.
5
Preparing for Patient-Customized N-of-1 Antisense Oligonucleotide Therapy to Treat Rare Diseases.为治疗罕见病的患者定制的 N-of-1 反义寡核苷酸治疗做准备。
Genes (Basel). 2024 Jun 21;15(7):821. doi: 10.3390/genes15070821.
6
Neuroimaging to Facilitate Clinical Trials in Huntington's Disease: Current Opinion from the EHDN Imaging Working Group.神经影像学在亨廷顿病临床试验中的应用：EHDN 影像学工作组的最新观点。
J Huntingtons Dis. 2024;13(2):163-199. doi: 10.3233/JHD-240016.
7
Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.脊髓炎作为托非生治疗超氧化物歧化酶1相关性肌萎缩侧索硬化症的副作用。
J Neurol. 2024 Apr;271(4):2114-2118. doi: 10.1007/s00415-023-12130-1. Epub 2023 Dec 9.
8
Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington's disease.基于片段的虚拟筛选鉴定出亨廷顿病的首个临床前候选药物。
Sci Rep. 2022 Nov 16;12(1):19642. doi: 10.1038/s41598-022-21900-2.
9
Towards Personalized Allele-Specific Antisense Oligonucleotide Therapies for Toxic Gain-of-Function Neurodegenerative Diseases.针对功能获得性毒性神经退行性疾病的个性化等位基因特异性反义寡核苷酸疗法
Pharmaceutics. 2022 Aug 16;14(8):1708. doi: 10.3390/pharmaceutics14081708.
10
[Disease-modifying treatment approaches in Huntington disease : Past and future].[亨廷顿舞蹈症的疾病修饰治疗方法：过去与未来]
Nervenarzt. 2022 Feb;93(2):179-190. doi: 10.1007/s00115-021-01224-8. Epub 2021 Nov 11.
N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.
4
Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.依库珠单抗治疗婴儿型脊髓性肌萎缩症的疗效观察
N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.